US Patent No: 5,475,092

Number of patents in Portfolio can not be more than 2000

Cell binding agent conjugates of analogues and derivatives of CC-1065

4 Status Updates

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Novel cytotoxic agents comprising a cell binding agent chemically linked to one or more analogue or derivative of CC-1065 are described. The therapeutic use of the cytotoxic agents is also described. These cytotoxic agents have therapeutic use because they deliver the cytotoxic drugs to a specific cell population in a targeted fashion.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
IMMUNOGEN, INC.WALTHAM, MA102

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Blattler, Walter A Brookline, MA 33 1002
Chari, Ravi V J Newton, MA 72 982
Goldmakher, Viktor S Newton, MA 17 275

Cited Art Landscape

Patent Info (Count) # Cites Year
 
BRISTOL-MYERS SQUIBB COMPANY (1)
* 4,301,248 Fermentation process for making rachelmycin 5 1980
 
XEROX CORPORATION (1)
* 5,106,951 Antibody conjugates 66 1989
 
CheckFree Services Corporation (1)
7,809,639 System and method to provide interoperable service across multiple clients 6 2002
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (1)
* 5,045,451 Methods for screening antibodies for use as immunotoxins 73 1988
 
UPJOHN COMPANY, THE (1)
* 4,912,227 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds 36 1986
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
LUDWIG INSTITUTE FOR CANCER RESEARCH (1)
9,072,798 Specific binding proteins and uses thereof 0 2010
 
Other [Check patent profile for assignment information] (1)
9,243,067 Humanized anti-CXCR5 antibodies, derivatives thereof and their use 0 2013
 
IMMUNOGEN, INC. (51)
6,340,701 Cytotoxic agents comprising taxanes and their therapeutic use 48 2000
6,372,738 Cytotoxic agents comprising taxanes and their therapeutic use 23 2001
6,436,931 Cytotoxic agents comprising taxanes and their therapeutic use 32 2002
6,756,397 Prodrugs of CC-1065 analogs 23 2002
* 2003/0199,519 Prodrugs of CC-1065 analogs 4 2002
6,706,708 Cytotoxic agents comprising taxanes and their therapeutic use 11 2002
7,390,898 Cytotoxic agents containing novel potent taxanes and their therapeutic use 3 2003
* 2004/0024,049 Cytotoxic agents containing novel potent taxanes and their therapeutic use 6 2003
7,008,942 Cytotoxic agents comprising taxanes and their therapeutic use 3 2003
7,049,316 Prodrugs of CC-1065 analogs 9 2003
* 2004/0109,867 Prodrugs of CC-1065 analogs 3 2003
7,374,762 Drug conjugate composition 10 2004
7,495,114 Cytotoxic agents containing novel potent taxanes and their therapeutic use 3 2004
7,414,073 Cytotoxic agents containing novel potent taxanes and their therapeutic use 3 2004
7,217,819 Cytotoxic agents comprising taxanes and their therapeutic use 3 2005
7,388,026 Prodrugs of CC-1065 analogs 6 2005
* 2006/0009,462 Prodrugs of CC-1065 analogs 3 2005
7,528,130 Cytotoxic agents comprising taxanes and their therapeutic use 3 2006
7,276,499 Cytotoxic agents comprising taxanes and their therapeutic use 3 2006
* 2006/0182,750 Process for preparing stable drug conjugates 10 2006
9,114,179 Immunoconjugate formulations 0 2006
* 2007/0031,402 Immunoconjugate formulations 39 2006
7,811,572 Process for preparing purified drug conjugates 2 2006
* 2007/0048,314 Process for preparing purified drug conjugates 6 2006
7,514,080 Drug conjugate composition 9 2006
7,501,120 Drug conjugate composition 8 2006
7,494,649 Drug conjugate composition 8 2006
* 2007/0009,539 Drug conjugate composition 1 2006
7,655,660 Prodrugs of CC-1065 analogs 8 2007
* 2007/0135,346 Prodrugs of CC-1065 analogs 4 2007
8,840,898 Immunoconjugates targeting syndecan-1 expressing cells and use thereof 0 2007
* 2007/0183,971 IMMUNOCONJUGATES TARGETING SYNDECAN-1 EXPRESSING CELLS AND USE THEREOF 2 2007
7,550,609 Cytotoxic agents comprising taxanes and their therapeutic use 3 2007
7,476,669 Cytotoxic agents comprising taxanes and their therapeutic use 3 2007
7,585,857 Cytotoxic agents comprising taxanes and their therapeutic use 7 2007
7,655,661 Prodrugs of CC-1065 analogs 6 2008
* 2008/0260,685 PRODRUGS OF CC-1065 ANALOGS 3 2008
8,012,978 Prodrugs of CC-A1065 analogs 0 2008
* 2009/0028,821 PRODRUGS OF CC-A1065 ANALOGS 5 2008
9,011,864 Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates 0 2008
* 2009/0181,038 METHOD OF DECREASING CYTOTOXIC SIDE-EFFECTS AND IMPROVING EFFICACY OF IMMUNOCONJUGATES 2 2008
8,012,485 Drug conjugate composition 5 2009
7,906,545 Prodrugs of CC-1065 analogs 1 2009
8,383,122 Process for preparing purified drug conjugates 2 2010
* 2011/0166,319 PROCESS FOR PREPARING PURIFIED DRUG CONJUGATES 2 2010
9,238,690 Non-antagonistic EGFR-binding molecules and immunoconjugates thereof 0 2011
8,790,649 EGFR-binding molecules and immunoconjugates thereof 2 2011
8,795,673 Preparation of maytansinoid antibody conjugates by a one-step process 0 2012
9,233,171 Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugate 0 2012
8,933,205 Process for preparing purified drug conjugates 0 2013
9,125,896 EGFR-binding molecules and immunoconjugates thereof 0 2013
 
The Scripps Research Institute (2)
* 6,262,271 ISO-CBI and ISO-CI analogs of CC-1065 and the duocarmycins 17 2000
6,486,326 iso-CBI and iso-CI analogs of CC-1065 duocarmycins 17 2001
 
ELUTEX LTD. (2)
* 2006/0013,850 Electropolymerizable monomers and polymeric coatings on implantable devices prepared therefrom 59 2005
* 2009/0123,514 Electropolymerizable Monomers and Polymeric Coatings on Implantable Devices Prepared Therefrom 1 2006
 
RIGEL PHARMACEUTICALS, INC. (1)
* 2005/0215,614 Substituted indoles and their use as hcv inhibitors 12 2005
 
PROLX PHARMACEUTICALS CORP. (2)
6,552,060 Asymmetric disulfides and methods of using same 6 1998
* 2003/0176,512 Asymmetric disulfides and methods of using same 3 2003
 
E. R. SQUIBB & SONS, L.L.C. (22)
7,129,261 Cytotoxic agents 39 2002
6,989,452 Disulfide prodrugs and linkers and stabilizers useful therefor 31 2002
7,691,962 Chemical linkers and conjugates thereof 22 2005
7,517,903 Cytotoxic compounds and conjugates 20 2005
* 2006/0024,317 Chemical linkers and conjugates thereof 16 2005
* 2006/0004,081 Cytotoxic compounds and conjugates 10 2005
7,498,302 Disulfide prodrugs and linkers and stabilizers useful therefor 7 2005
* 2005/0272,798 Disulfide prodrugs and linkers and stabilizers useful therefor 10 2005
7,507,420 Peptidyl prodrugs and linkers and stabilizers useful therefor 17 2005
* 2006/0013,860 Peptidyl prodrugs and linkers and stabilizers useful therefor 3 2005
7,714,016 Cytotoxic compounds and conjugates with cleavable substrates 10 2006
8,124,738 Human monoclonal antibodies to CD70 6 2006
* 2009/0028,872 HUMAN MONOCLONAL ANTIBODIES TO CD70 6 2006
7,847,105 Methods and compounds for preparing CC-1065 analogs 5 2006
7,968,586 Cytotoxic compounds and conjugates 6 2006
8,461,117 Chemical linkers and cleavable substrates and conjugates thereof 0 2007
8,664,407 Chemical linkers with single amino acids and conjugates thereof 0 2008
* 2010/0113,476 CHEMICAL LINKERS WITH SINGLE AMINO ACIDS AND CONJUGATES THEREOF 16 2008
* RE41252 Peptidyl prodrugs and linkers and stabilizers useful therefor 2 2008
8,034,959 Methods of treating cancer with an antibody-drug conjugate 6 2009
7,977,465 Peptidyl prodrugs and linkers and stabilizers useful therefor 5 2009
8,399,403 Chemical linkers and conjugates thereof 0 2009
 
SANOFI (11)
8,460,667 EPHA2 receptor antagonist antibodies 1 2007
8,153,765 Anti-CD38 antibodies for the treatment of cancer 0 2007
8,647,622 Humanized anti-CXCR5 antibodies, derivatives thereof and their use 1 2008
* 2011/0027,266 Humanized anti-CXCR5 antibodies, derivatives thereof and their use 0 2008
8,388,965 Antibodies that bind IL-4 and/or IL-13 and their uses 4 2008
* 2010/0226,923 ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES 3 2008
8,404,678 Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use 0 2010
8,668,910 Antibodies that specifically bind to the EphA2 receptor 0 2010
9,228,019 Humanized anti-CXCR5 antibodies, derivatives thereof and their use 0 2013
9,175,087 Humanized anti-CXCR5 antibodies, derivatives thereof and their use 0 2013
8,980,262 Humanized anti-CXCR5 antibodies, derivatives thereof and their use 0 2013
 
REDWOOD BIOSCIENCE, INC. (1)
9,238,878 Aldehyde-tagged protein-based drug carriers and methods of use 0 2010
 
XENCOR, INC. (1)
8,637,641 Antibodies with modified isoelectric points 0 2011
 
BIOTEST AG (2)
9,221,914 Agents targeting CD138 and uses thereof 0 2008
* 2009/0175,863 AGENTS TARGETING CD138 AND USES THEREOF 2 2008
 
ALCHEMIA ONCOLOGY PTY LIMITED (10)
8,287,894 Hyaluronan as a drug pre-sensitizer and chemo-sensitizer in the treatment of disease 3 2005
* 2005/0267,069 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease 5 2005
9,066,919 Hyaluronan as a chemo-sensitizer in the treatment of cancer 0 2005
8,388,993 Hyaluronan-chemotherapeutic agent formulations for the treatment of colon cancer 3 2006
* 2006/0263,395 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease 5 2006
8,937,052 Therapeutic protocols using hyaluronan 0 2006
* 2009/0054,537 THERAPEUTIC PROTOCOLS USING HYALURONAN 5 2006
8,623,354 Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment 3 2006
* 2009/0306,012 THERAPEUTIC PROTOCOLS 6 2009
8,741,970 Composition and method for the enhancement of the efficacy of drugs 2 2011
 
JCRT Radiation Oncology Support Services, Inc. (2)
6,368,598 Drug complex for treatment of metastatic prostate cancer 17 1998
* 2005/0233,948 Drug complex for treatment of metastatic prostate cancer 18 2005
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (1)
9,023,356 Treatment method using EGFR antibodies and SRC inhibitors and related formulations 0 2008
 
ARCHEMIX LLC (1)
8,853,376 Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics 0 2011
 
MEMORIAL SLOAN-KETTERING CANCER CENTER (1)
9,169,328 Antibodies to MUC16 and methods of use thereof 0 2011
 
THE GENERAL HOSPITAL CORPORATION (1)
8,900,549 Compositions and methods for delivering a substance to a biological target 0 2009
 
MEDAREX, L.L.C. (2)
7,087,600 Peptidyl prodrugs and linkers and stabilizers useful therefor 30 2002
* 2010/0150,950 HUMAN ANTIBODIES THAT BIND CD70 AND USES THEREOF 7 2007
 
BAYLOR COLLEGE OF MEDICINE (1)
* 5,780,446 Formulations of vesicant drugs and methods of use thereof 20 1996
 
THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (1)
9,133,239 Compositions and methods for inhibiting matrix metalloproteinase (MMP)-mediated cell migration 0 2011
 
SYNTARGA B.V. (1)
8,889,868 CC-1065 analogs and their conjugates 0 2009
 
Archemix Corp. (1)
* 2004/0022,727 Aptamer-toxin molecules and methods for using same 18 2003
 
DANA-FARBER CANCER INSTITUTE, INC. (1)
9,090,693 Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease 0 2008
 
COMPUGEN LTD. (2)
7,745,391 Human thrombospondin polypeptide 70 2006
* 2007/0083,334 Methods and systems for annotating biomolecular sequences 72 2006
 
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (1)
* 2003/0099,684 Electropolymerizable monomers and polymeric coatings on implantable devices 28 2002
* Cited By Examiner